Baker McKenzie Steers Servier On $450M Autism Drug Buy
French pharmaceutical group Servier said Monday it has acquired a potential treatment for the most common genetic cause of autism from U.K.-based biotech Kaerus Bioscience Ltd., in a transaction that could...To view the full article, register now.
Already a subscriber? Click here to view full article